Heterotandem bicyclic peptide complexes

A heterotandem bicyclic peptide complex comprising:

• (a) a first peptide ligand which binds to CD137 on an immune cell;
• conjugated via a linker to
• (b) a second peptide ligand which binds to a component present on a cancer cell, wherein the component present on a cancer cell is EphA2;
• wherein each of said peptide ligands comprises a polypeptide comprising three cysteine residues, separated by two loop sequences, and a molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that two polypeptide loops are formed on the molecular scaffold,
• wherein the first peptide ligand is a CD137 binding bicyclic peptide ligand comprising an amino acid sequence selected from:
• CiIEEGQYCiiFADPY[Nle]Ciii (SEQ ID NO:
• 1);
• Ci[tBuAla]PE[D-Ala]PYCiiFADPY[Nle]Ciii (SEQ ID NO:
• 3);
• CiIEEGQYCiiF[D-Ala]DPY[Nle]Ciii (SEQ ID NO:
• 4);
• Ci[tBuAla]PK[D-Ala]PYCiiFADPY[Nle]Ciii (SEQ ID NO:
• 5);
• Ci[tBuAla]PE[D-Lys]PYCiiFADPY[Nle]Ciii (SEQ ID NO:
• 6);
• Ci[tBuAla]P[K(PYA)][D-Ala]PYCiiFADPY[Nle]Ciii (SEQ ID NO:
• 7);
• Ci[tBuAla]PE[D-Lys(PYA)]PYCiiFADPY[Nle]Ciii (SEQ ID NO:
• 8);
• CiIEE[D-Lys(PYA)]QYCiiFADPY(Nle)Ciii (SEQ ID NO:
• 9);
• and
• [dCi][dI][dE][dE][K(PYA)][dQ][dY][dCii][dF][dA][dD][dP][dY][dNle][dCiii] (SEQ ID NO:
• 10);
• and
• wherein the second peptide ligand is an EphA2 binding bicyclic peptide ligand comprising an amino acid sequence selected from:
• Ci[HyP]LVNPLCiiLHP[dD]W[HArg]Ciii (SEQ ID NO:
• 2);
• and
• CiLWDPTPCiiANLHL[HArg]Ciii (SEQ ID NO:
• 11);
• wherein Ci, Cii and Ciii represent first, second and third cysteine residues, respectively, Nle represents norleucine, tBuAla represents t-butyl-alanine, PYA represents 4-pentynoic acid, HyP represents hydroxyproline, dD represents aspartic acid in D-configuration, and HArg represents homoarginine, or a pharmaceutically acceptable salt thereof.